基于中性和耐药相关标记物基因分型对治疗失败的疗效试验中抗间日疟原虫药物的特征描述。
Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.
机构信息
Vector Borne Diseases Unit, PNG Institute of Medical Research, Goroka, Papua New Guinea.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4479-81. doi: 10.1128/AAC.01552-10. Epub 2011 Jun 27.
Abstract
Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates. Application of recrudescence-reinfection genotyping and drug resistance single-nucleotide polymorphism typing to a 4-arm comparative efficacy trial illustrated that molecular approaches can assist in understanding the relative contributions of true drug resistance (recurrent with same genotype) and new infections to treatment failure. The PCR-corrected adequate clinical and parasitologic response may constitute an informative secondary endpoint in future P. vivax drug trials.
摘要
间日疟原虫干预试验通常报告未经校正的治疗失败率。应用复发再感染基因分型和药物耐药性单核苷酸多态性分型对四臂比较疗效试验的研究表明，分子方法有助于了解真正的药物耐药性（与相同基因型复发）和新感染对治疗失败的相对贡献。PCR 校正后的充分临床和寄生虫学反应可能成为未来间日疟原虫药物试验的一个有用的次要终点。
相似文献
1
Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.
Antimicrob Agents Chemother. 2011 Sep;55(9):4479-81. doi: 10.1128/AAC.01552-10. Epub 2011 Jun 27.
2
Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria.
J Infect Dis. 2019 Jan 7;219(2):315-322. doi: 10.1093/infdis/jiy484.
3
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.
Trends Parasitol. 2012 Nov;28(11):522-9. doi: 10.1016/j.pt.2012.08.005. Epub 2012 Oct 5.
4
Polymorphisms in genes associated with drug resistance of Plasmodium vivax in India.
Parasitol Int. 2019 Jun;70:92-97. doi: 10.1016/j.parint.2019.03.001. Epub 2019 Mar 2.
5
Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in Central China.
Korean J Parasitol. 2012 Dec;50(4):379-84. doi: 10.3347/kjp.2012.50.4.379. Epub 2012 Nov 26.
6
Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal.
Malar J. 2011 Apr 1;10:75. doi: 10.1186/1475-2875-10-75.
7
Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka.
Malar J. 2007 Mar 9;6:28. doi: 10.1186/1475-2875-6-28.
8
Molecular monitoring of dihydrofolatereductase (dhfr) and dihydropteroatesynthetase (dhps) associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates of Palawan, Philippines.
Acta Trop. 2018 Apr;180:81-87. doi: 10.1016/j.actatropica.2018.01.006. Epub 2018 Jan 17.
9
Assessing the in vitro sensitivity with associated drug resistance polymorphisms in Plasmodium vivax clinical isolates from Delhi, India.
Exp Parasitol. 2021 Jan;220:108047. doi: 10.1016/j.exppara.2020.108047. Epub 2020 Nov 20.
10
Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region.
Antimicrob Agents Chemother. 2009 Aug;53(8):3561-4. doi: 10.1128/AAC.00004-09. Epub 2009 May 18.
引用本文的文献
1
Molecular detection of antimalarial drug resistance in from returned travellers to NSW, Australia during 2008-2018.
Pathogens. 2020 Feb 5;9(2):101. doi: 10.3390/pathogens9020101.
2
Malaria Epidemiology at the Clone Level.
Trends Parasitol. 2017 Dec;33(12):974-985. doi: 10.1016/j.pt.2017.08.013. Epub 2017 Sep 28.
3
Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.
Clin Infect Dis. 2017 Jan 15;64(2):166-174. doi: 10.1093/cid/ciw706. Epub 2016 Oct 20.
4
Diagnosis and Treatment of Plasmodium vivax Malaria.
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):35-51. doi: 10.4269/ajtmh.16-0171. Epub 2016 Oct 5.
5
Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea.
Malar J. 2015 Oct 9;14:399. doi: 10.1186/s12936-015-0879-9.
6
Plasmodium vivax Diversity and Population Structure across Four Continents.
PLoS Negl Trop Dis. 2015 Jun 30;9(6):e0003872. doi: 10.1371/journal.pntd.0003872. eCollection 2015.
7
Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study.
Malar J. 2015 Mar 21;14:121. doi: 10.1186/s12936-015-0624-4.
8
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.
PLoS Med. 2014 Dec 30;11(12):e1001773. doi: 10.1371/journal.pmed.1001773. eCollection 2014 Dec.
9
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.
Lancet Infect Dis. 2014 Oct;14(10):982-91. doi: 10.1016/S1473-3099(14)70855-2. Epub 2014 Sep 8.
10
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
Antimicrob Agents Chemother. 2014;58(1):432-9. doi: 10.1128/AAC.01437-13. Epub 2013 Nov 4.
本文引用的文献
1
The international limits and population at risk of Plasmodium vivax transmission in 2009.
PLoS Negl Trop Dis. 2010 Aug 3;4(8):e774. doi: 10.1371/journal.pntd.0000774.
2
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Antimicrob Agents Chemother. 2010 Jan;54(1):52-9. doi: 10.1128/AAC.00679-09. Epub 2009 Oct 19.
3
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite.
Lancet Infect Dis. 2009 Sep;9(9):555-66. doi: 10.1016/S1473-3099(09)70177-X.
4
High prevalence and fixation of Plasmodium vivax dhfr/dhps mutations related to sulfadoxine/pyrimethamine resistance in French Guiana.
Am J Trop Med Hyg. 2009 Jul;81(1):19-22.
5
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials.
J Infect Dis. 2009 Apr 1;199(7):1074-80. doi: 10.1086/597303.
6
A trial of combination antimalarial therapies in children from Papua New Guinea.
N Engl J Med. 2008 Dec 11;359(24):2545-57. doi: 10.1056/NEJMoa0804915. Epub 2008 Dec 8.
7
Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes.
Antimicrob Agents Chemother. 2008 Dec;52(12):4233-40. doi: 10.1128/AAC.00578-08. Epub 2008 Sep 22.
8
Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1.
J Infect Dis. 2008 Aug 1;198(3):409-17. doi: 10.1086/589882.
9
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia.
PLoS Med. 2008 Jun 17;5(6):e128. doi: 10.1371/journal.pmed.0050128.
10
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea.
PLoS Med. 2008 Jun 17;5(6):e127. doi: 10.1371/journal.pmed.0050127.
Zotero 插件